Psychiatric Times

Psychiatric Times Welcome to Psychiatric Times on Facebook, a place to talk about mental health and psychiatry.

This season, we give thanks for the mental health professionals, researchers, and advocates who work tirelessly to suppo...
11/27/2025

This season, we give thanks for the mental health professionals, researchers, and advocates who work tirelessly to support wellness and healing. 🦃💙
Wishing you peace and connection this Thanksgiving.

📣 A New Era in Clozapine Education Are you confident prescribing clozapine? Through a partnership between S&PAA and AAPP...
11/19/2025

📣 A New Era in Clozapine Education
Are you confident prescribing clozapine?
Through a partnership between S&PAA and AAPP: Clozapine Education Modules, designed for busy prescribers who want expert, evidence-based answers—fast.
From “When do I start?” to “How do I manage side effects?”
Featuring expert, Megan Ehret, PharmD, MS, BCPP, FAAPP
Short, focused modules—each under an hour

🔗Don’t miss your chance to be the first to access this FREE learning series: https://hubs.li/Q03SF_5y0

&PAA

The FDA has granted a label expansion for the deep transcranial magnetic stimulation system that makes the treatment ava...
11/14/2025

The FDA has granted a label expansion for the deep transcranial magnetic stimulation system that makes the treatment available as an adjunct therapy for adolescents aged 15 to 21 years who have major depressive disorder.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Placebo treatments can yield clinically meaningful improvements across psychiatric disorders. A new study found the stro...
11/14/2025

Placebo treatments can yield clinically meaningful improvements across psychiatric disorders. A new study found the strongest effects in depression and anxiety, and the weakest effects seen in schizophrenia and OCD.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

In the Vibrance-2 study, once-daily alixorexton met the dual primary endpoints, demonstrating statistically significant ...
11/13/2025

In the Vibrance-2 study, once-daily alixorexton met the dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared with placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week 8.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Today, we honor and thank the brave men and women who have served our country.Psychiatric Times recognizes the unique me...
11/11/2025

Today, we honor and thank the brave men and women who have served our country.
Psychiatric Times recognizes the unique mental health challenges faced by veterans and remains committed to advancing education, research, and compassionate care for those who have sacrificed so much.

In a phase 2b open-label extension study of AtaiBeckley's BPL-003 in patients with treatment-resistant depression, inves...
11/10/2025

In a phase 2b open-label extension study of AtaiBeckley's BPL-003 in patients with treatment-resistant depression, investigators found that a 12 mg dose of BPL-003 administered 8 weeks after a 0.3 mg, 8 mg, or 12 mg dose of BPL-003 was generally well-tolerated and provided additional rapid, clinically meaningful antidepressant effects, which were sustained for up to 8 weeks.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Address

Cranbury, NJ

Alerts

Be the first to know and let us send you an email when Psychiatric Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Psychiatric Times:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram